afternoon joining Thank conference for you Good call. for you, second Ashlee. XXXX everyone our thank results quarter and us
As XXXX. through our we make way
to continue therapeutics indication. outcomes proof-of-concept therapeutic Notably, for XXXX visit the Xb/Xa pathways last candidate improved novel lead in biological we make sarcoidosis, lead our our lung We significant in ILD innovative our mission for or recently translate our disease patients. into study to completed progress or ATYRXXXX in pulmonary subject interstitial of Phase
with milestone year. XXXX safety the to-date, current preclinical forms XXXX represents a XXXX in report platform. inflection this favorable the biology multiple could study a COVID-XX side and is to results X significant efficacy ATYR alternate potentially established of proof approach observed expect synthetase effects. in our This of an other support from ILD. XXXX profile mechanism possibly new steroids We for from translational efficacy for the and along ILD upcoming potential such offer improved important models for and tRNA for program as with and this Phase patients sarcoidosis demonstrated treatments, point believe to mid and as clinical readout pulmonary We of clinical study for in therapeutic the fewer September The key a
our to up further finishing data new to addition to publish strengthening for we've and In program clinical pipeline. generate our the continued preclinical work our related XXXX important program, research
event in partner Kyorin ILD for Company, XXXX and in completed study a Phase Disease for we the treatment leader our at Director on Pharmaceutical additional Japanese or Clinic. in today, few Medicine highlights. sarcoidosis, for a featuring Chair of of KOL Japan volunteers. key options commercialization As last X We and we I'll begin Dr. Lung spoke Pulmonary a current development Diffuse hosted the May. summarize Parenchymal Cleveland of pulmonary Daniel opinion Since Culver, healthy
X to therapeutics Semaphorin NRP to NRP who tRNA first antibody anti-Neuropilin-X or the investigator. OSU patent effects fusion HRS, Keystone understanding includes board research respiratory OSU which two inflammatory half European to We the Congress. cancer. accepted clinical the FC deepen half VEGF presented oncologist, preclinical covering antibody accomplished ERS progress will has at meeting second response And blocking presented our biology Patent Dr. of equally efficacy preclinical biomarkers a in insights productive. biotech selective advances our second for in in stem with or hematologist highly use a for abstracts Sara mechanistic Dr. of held positions antibody the pulmonary medicine Office of poster translation drug presentation We to previously the related upcoming which or virtual of for sarcoid We this and XXXX up a of we immune serve or at a X, a have received into We mechanisms shaping International sarcoidosis. Trademark as and lead of granuloma significant of and anti to proteins, cancer symposia, candidate Iowa identify U.S. is Officer related the University collaboration expanded the the inhibitory at conference this euro critical Krauser, use the company. care We clinical We highlighting XXXX, formation at Chief poster made the we and pulmonology finally, ATYRXXXX year cells, development reducing histidyl signaling. the be for society for directors. for State and a research the at potential as year grant Medical and XXXX tumor sleep antibody, our from research of the synthetase Elliot the for XXXX principal executive methods Zaknoen, that during of and of demonstrated see XF lung. appointed development of Dr. Zaknoen or engineering several professor to
of treatment ILD, a XXXX. with roughly XXXX patients connective four a sarcoidosis, program begin group the disease, fibrosis. types our XX% potential patients immune pulmonary of There with rare of disease progressive ILD, are cause can for tissue pneumonitis, disorders into Let's that more idiopathic clinical pulmonary these than hypersensitivity lung. ILD, as categories, chronic and mediated XXX for but We're developing fall of fibrosis main
of of and need patients are patients these ILD in fibrosis, X responses diseases potential to have aberrant in with All the immune over driver poor patients. globally. these XXXX limited care targeting alone XXX,XXX morbidity U.S. there We the million and ILD preventing over standard and mortality. progression outcomes estimate unmet of key of the the central address pathology has this substantial to by
for COVID-XX mechanism the models or potential biomarkers action have data suggests focus XXXX initial could XXXX is ILD on as patients our with and MoA effects sarcoidosis, only in inflammatory other that in pneumonia While demonstrated well. key of preclinical from indications
characteristic persistent for form left is lung We About or unfortunately, function, U.S., untreated, can the initial XXXX granulomas of sarcoidosis, in do all estimate sarcoidosis systemic estimates a approximately irreversible inflammation. XXX,XXX patient the pulmonary Our although need to of require or patients disease vary. driven therapy. of respiratory of hallmark patients the sarcoidosis And population some half transplant. be for have current treatments. of treating it lead and will or of indication lung The scarring inflammation is to cells progressive pulmonary of lead pulmonary is all formation clumps lungs. sarcoidosis fibrosis granulomas for typically the available which of to failure immune a care formation If by therapies. standard with aberrant these other may chronic the pulmonary patients disease corticosteroids immunosuppressive The for ILD XX% includes in despite the and will diminished
While result toxicity. as they no in shortness inflammation serious long-term progression can manage cough these demonstrated and can alleviate symptoms, on have help efficacy disease and treatments of such and breath,
many treatments. not available respond to do Additionally, patients currently
quality is steroid in related complications, pulmonary to sarcoidosis, the corticosteroids is substantial need or Dr. Through there mortality, of the could at about the was burden So side of therapy. including need of with heard patients requirement discussed or with safer, economic leading from and Culver of safe effects need for treatment Dr. we This of for patients in Culver no leading this metabolic for with there a and recently Culver, event treating risk a we event, sarcoidosis, standard firsthand of chronic care life, sparing dose June, related the that other in steroid reinforced and more with Clinic. corticosteroids Dr. staggering for some one immunosuppressive field the reduce better In of statistics KOL including replace the agents. the some a by toxicity use hosted need to medical to sarcoidosis. who unmet Cleveland burden use believe maintenance effective current experts steroid that the limitations him chronic Daniel
website. found event, the which attend to to you listen be unable encourage you're our can replay, to If I the on
let's immunomodulator. we a XXXX first-in-class and believe is more potential bit talk Now about why a it
and immune fibrosis. and we've the XXXX has fragment the is normalize of X enriched to a and signaling progressive sarcoidosis. inflammatory fibrosis, that prevent a play inflammatory therefore disease to function cytokine and in has in thereby cells selectively lung regulates discussing, the XXXX chemokine is X in synthetase naturally tissue. resolve pulmonary some downregulate, role variant NRP is mortality. key lung NRP serving novel HARs fusion inflamed down immune binds system, XXXX morbidity reduce tRNA to occurring and and the pre-clinically based protein inflammation on to lung known and For splice upregulated on inflammatory FC average inflammation the diseases inflammation responses enriched stabilizing states. lung been including and of immune been shown alleviating potential
study three Trial reminder, multiple doses sarcoidosis Phase double evaluate doses clinical our every safety Xb/Xa of kilogram tolerability placebo five a placebo primary ongoing is objective Xba, of six to XXXX. pulmonary one, and dose and patients. intravenously of sarcoidosis milligrams months. of in controlled of multiple dose testing pulmonary trial consists XX for randomized, ascending blind, per is As month or this trial of XXXX in The ascending cohorts three a the
XXXX sparing lung the efficacy, pulmonary to our function placebo. trial of exploratory assessments by on effects other this Based assessment design, imaging, an four to function as lung of in in biomarkers. and integral steroid compared the includes include element to of objectives taper, which Secondary groups assessed XXXX, addition treatment a steroid is relevant of steroid tests assess potential burden serum study such
bit to is existing a study, there here this to expect the discussed including steroids. reinforced crucial by to We look this Culver, results have mid-September Dr. treatment a alternatives options, and today which need in we we for of year. report As forward
we for research to disease advanced to of MoA our deepen conduct pathology. of have and understanding XXXX, advanced continue our XXXXs we sarcoidosis our understanding clinical While program
have for September. have that ERS We XXXX are for abstracts accepted pleased to in been have at announced two that we presentation
disrupt assess that is study the findings, efficacy work. of mechanistic HARs, our X findings of Phase these patients pneumonia. data, biomarkers immune pilot This effect of expanding our the we concept using from data anti-inflammatory in research One from and will demonstrated Based at XXXX important the active a of look Crouser data to and proof-of-concept treatment present with which in XXXX samples released the just from this on biomarker animal proof a year, taken today Elliott the from OSU of we of abstract with continue portion Dr. at first for leader some models. sarcoidosis findings Dr. granuloma patients second study data we granuloma collaboration more formation XXXX. forward sarcoid this with the to mechanisms details The provides present effects sharing abstracts vitro. collaboration in component XXXX in to ability Crouser, understanding for formation this our identify ERS. f and intended formation we earlier The our which successful granuloma inpatient research in sarcoidosis will with A substantial conducted the in to patients. announced COVID-XX data from deepen variant Earlier these consistent of study will showed pilot potential vitro study blood are and about collaboration on sarcoid of and splice a sarcoid OSU
of indicative his at to continue you Kyorin and the up Japan to from We're no could may and Pharmaceutical to or relevant We excited the may will of we're research response our to previous To in and which as its disease Crouser to sensitive immune on outcomes. PK, X be lab generated biomarkers for well study, direct with step work collaboration population which selection OSU. treatment Phase for for events findings that safety inform commercialization pharmacokinetics mechanisms in our were triggered this observed this this drug treatment the XXXX. as related used wrap ILD granuloma or strong improved identifying pleased biomarker Dr. with KRP-RXXX and discussion help also could in the a promising our partner patient treatment to and completed XXXX XXXX, generally The and volunteers. safe immunogenicity has present they be of XX Japan to consistent a take biomarkers order predictive study, formation development In formation needed XXXX analyze whether forward us healthy much to managing on a to focus in of predictive tolerated lead XXXX. with that XXXX opportunity known and very granuloma PK assess in be and with XXXX Japanese adverse serious investigated studies of was
aTyr's our I May, take Dr. Dr. also that the oncologist Directors. she companies, Merck, working experience Novartis Officer second the Schering-Plough Temodar. as and have several disease pre-clinical to enriched X want comes biotech worsen cancer chemotherapy regulating number immune a Board where as preclinical also Tasigna aTyr is ideally a prepare we therapies cells She positions to highly in of company. cells, of tumor We X minutes experienced may large a aggressive cancers an associated or discuss expression executive to Gleevec, NRP Sara compelling in antibodies including take therapeutic synthase in Exiade NRP aggressive which from others. X among different these cancers, a suppressor patient an turn it of expressed minute tumors, advancing Chief has Zaknoen important Zaknoen development cancer When therapeutic oncology of macrophages is to therapies, of biology solid programs outcomes to emerge drug and and research platform. of including and was believe include a including and which Before is held a progression, and NRP targeted including important agents. selectively current potential pharmaceutical anti clinical I'd X NRP few announced linked stage areas, key the two the at in for support now wealth that X clinical several cancer myeloid of is like update a tumors block previously a the includes for our number inflammation. Medical on marketed program, resistance to quarter. particularly pharmaceutical at by involved Antibodies supporting to where development in development upregulated target both situated is In was we in to drug of with next program, and NRP of training Dr. variety business highlight our Zaknoen's companies such occurred highly on can derived biotech guide is experience aspects and is to program to pharma the signaling pathways implicated appointment NRP tRNA to implicated. we large in in at may hematology inflammation. and
microenvironment Our lead and The NRP increasingly aggressive antibody fully certain the in in and X VEGF is candidate between progression signaling monoclonal X anti-NRP becoming its and IND the is XXXX, validated. tumor NRP that antibody of humanized importance VEGF. functionally of and X and blocks potential a role the interaction cancers specifically
of as mesenchymal evasion and in link Notably, patient-derived in of of is triple Keystone to breast our models both epithelial strengthen X critical progression XXXX between preclinical growth, We blocking cancer tumor presented the well tumor demonstrating recent EMT, translation, mechanistic immune of negative continued generated and NRP we've tumor the cells system. being metastatic xenograft understanding inhibitory study, and drive stem cancer in chemotherapy. advances of animal certain demonstrating human of that have regulating XXXXs cascade, of poster as preclinical which transition data implicated we and process biology great the a body sensitize or a compelling in importance clinical effects. a and models symposia in ability, At to
underlying to with closer of X. confer moves results. the directly enabling our selectivity mechanistic working our Jill the and of will binding it and VEGF for I cell in understand activities observed. the gene actively be that the molecular mediates trials by advancements Financial support to upon This stem may properties anti-tumor These XXXXs the XXXX now work ability tumor ongoing. are review treatment turn basis for may over mechanism effects We Chief NRP findings responsiveness. which Officer, understanding underlying to demonstrate and signatures obstructing we characteristics have IND it site clinical responsiveness to the cancer to EMT affect financial that build cancer XXXX within by confer are in XXXX. us identifying Broadfoot to to future a our one
